Subjects with arterial thrombotic events in the prior 12 months (axitinib has never been studied in this population)
Subjects who have had venous thrombotic events in the prior 6 months (axitinib has never been studied in this population)
Prior treatment with axitinib
InlytaÂ® (axitinib) and/or,
Prior therapy with bosutinib or axitinib
Patients with a history of hypersensitivity to bosutinib or axitinib
Known hypersensitivity to any component of axitinib or prior use of axitinib
Prior therapy with axitinib
Clinically significant organ/system disease unrelated to RCC that in the judgment of the investigator should preclude treatment with dalantercept or axitinib.
Any prior treatment with axitinib.
A morbidity (per the prescribing information) that would require starting a patient at a reduced dose of axitinib.
Patients who were assigned to an axitinib containing treatment arm in a previous clinical trial
Patients who were receiving axitinib tablets at the time their previous trial ended
Parts A and B only: Has received a prior course of axitinib.
